Advertisement

Annals of Hematology

, Volume 90, Issue 6, pp 693–699 | Cite as

Pilot study of pegylated interferon alpha-2a treatment during chemo- and radiotherapy and post-remission maintenance in patients with EBV-positive extranodal NK/T cell lymphoma

  • Sung-Yong Kim
  • Seok-Goo ChoEmail author
  • Sung-Won Kim
  • Byung-Ok Choi
  • Kyung-Sin Park
  • Jihyang Lim
  • Chang-Ki Min
  • Yong-Goo Kim
  • Jong-Wook Lee
  • Woo-Sung Min
Original Article

Abstract

The role of the Epstein–Barr virus (EBV) in the pathogenesis of extranodal natural killer/T-cell lymphoma (ENKTCL), and its resistance to chemotherapy raises the possibility of antiviral therapeutic strategies. The aim of this prospective pilot study was to evaluate the feasibility and effectiveness of antiviral treatment using pegylated interferon alpha-2a (pIFN α-2a) as an adjunct to induction and maintenance therapy in patients with ENKTCL. A total of seven patients with newly diagnosed EBV-positive ENKTCL were enrolled. Pegylated IFN α-2a was administered during induction chemoradiotherapy. If patients achieved a partial or complete response (PR or CR, respectively), high-dose chemotherapy with autologous stem cell transplantation (HDT/SCT) was given. After transplantation, maintenance therapy included pIFN α-2a for 3 years. Of the patients available for evaluation, all achieved a CR or PR after induction therapy but one patient relapsed before HDT/SCT. The event free survival and overall survival at 3 years were 50.0 ± 20.4% and 66.7 ± 19.2%, respectively. The 3-year disease-free survival after transplantation of the patients that received maintenance therapy was 80.0 ± 17.9%. The results of this pilot study indicated that pIFN α-2a containing induction and maintenance therapy was feasible and effective for ENKTCL.

Keywords

Extranodal NK/T cell lymphoma Epstein–Barr virus Interferon alpha-2a 

Notes

Acknowledgments

This study was supported by grants from the Korea Science and Engineering Foundation (R11-2002-098-08004-0) and from the Catholic Institute of Cell Therapy Basic Science Programs Foundation during the program year 2007. The study was, in part, sponsored by Roche Pharmaceutical.

References

  1. 1.
    Ishii H, Ogino T, Berger C, Kochli-Schmitz N, Nagato T, Takahara M, Nadal D, Harabuchi Y (2007) Clinical usefulness of serum EBV DNA levels of bamhi w and lmp1 for nasal NK/T-cell lymphoma. J Med Virol 79(5):562–572PubMedCrossRefGoogle Scholar
  2. 2.
    Greer JP (2006) Therapy of peripheral T/NK neoplasms. Hematology Am Soc Hematol Educ Program 331–337Google Scholar
  3. 3.
    Huang WT, Chang KC, Huang GC, Hsiao JR, Chen HH, Chuang SS, Chen TY, Su WC, Tsao CJ (2005) Bone marrow that is positive for EBV-encoded RNA-1 by in situ hybridization is related with a poor prognosis in patients with extranodal natural killer/T-cell lymphoma, nasal type. Haematologica 90(8):1063–1069PubMedGoogle Scholar
  4. 4.
    Ortaldo JR, Mason A, Rehberg E, Moschera J, Kelder B, Pestka S, Herberman RB (1983) Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J Biol Chem 258(24):15011–15015PubMedGoogle Scholar
  5. 5.
    Greiner JW, Guadagni F, Noguchi P, Pestka S, Colcher D, Fisher PB, Schlom J (1987) Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science (New York, NY) 235(4791):895–898CrossRefGoogle Scholar
  6. 6.
    Pestka S, Krause CD, Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202:8–32PubMedCrossRefGoogle Scholar
  7. 7.
    Faro A (1998) Interferon-alpha and its effects on post-transplant lymphoproliferative disorders. Springer Semin Immunopathol 20(3–4):425–436PubMedCrossRefGoogle Scholar
  8. 8.
    Garner JG, Hirsch MS, Schooley RT (1984) Prevention of Epstein–Barr virus-induced b-cell outgrowth by interferon alpha. Infect Immunity 43(3):920–924Google Scholar
  9. 9.
    Cho SG, Koh YB, Chang HS, Park G, Kang CS, Park JW, Min WS (2005) Successful treatment with splenectomy and interferon alpha against recurred hemophagocytic syndrome in remission state of anaplastic large cell lymphoma following high-dose therapy and autologous peripheral blood stem cell transplantation. Eur J Haematol 74(3):259–262PubMedCrossRefGoogle Scholar
  10. 10.
    Cheung MM, Chan JK, Lau WH, Foo W, Chan PT, Ng CS, Ngan RK (1998) Primary non-Hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16(1):70–77PubMedGoogle Scholar
  11. 11.
    Au WY, Lie AK, Liang R, Kwong YL, Yau CC, Cheung MM, Ngan KC, Lau WH, Wong KH, Yiu HY, Cheng HC, Au KH, Chan JK (2003) Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 14(11):1673–1676PubMedCrossRefGoogle Scholar
  12. 12.
    Longo DL, DeVita VT Jr, Duffey PL, Wesley MN, Ihde DC, Hubbard SM, Gilliom M, Jaffe ES, Cossman J, Fisher RI et al (1991) Superiority of promace-cytabom over promace-mopp in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 9(1):25–38PubMedGoogle Scholar
  13. 13.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586PubMedCrossRefGoogle Scholar
  14. 14.
    Ruiz G, Pena P, de Ory F, Echevarria JE (2005) Comparison of commercial real-time PCR assays for quantification of Epstein–Barr virus DNA. J Clin Microbiol 43(5):2053–2057PubMedCrossRefGoogle Scholar
  15. 15.
    Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (chop) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. New Engl J Med 328(14):1002–1006PubMedCrossRefGoogle Scholar
  16. 16.
    Au WY, Pang A, Choy C, Chim CS, Kwong YL (2004) Quantification of circulating Epstein–Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 104(1):243–249PubMedCrossRefGoogle Scholar
  17. 17.
    Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC (2002) Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 62(6):1920–1926PubMedGoogle Scholar
  18. 18.
    Sharp NA, Arrand JR, Clemens MJ (1989) Epstein–Barr virus replication in interferon-treated cells. J Gen Virol 70(Pt 9):2521–2526PubMedCrossRefGoogle Scholar
  19. 19.
    Delcayre AX, Lotz M, Lernhardt W (1993) Inhibition of Epstein–Barr virus-mediated capping of CD21/CR2 by alpha interferon (IFN-alpha): immediate antiviral activity of IFN-alpha during the early phase of infection. J Virol 67(5):2918–2921PubMedGoogle Scholar
  20. 20.
    Taguchi Y, Purtilo DT, Okano M (1994) The effect of intravenous immunoglobulin and interferon-alpha on Epstein-Barr virus-induced lymphoproliferative disorder in a liver transplant recipient. Transplantation 57(12):1813–1815PubMedGoogle Scholar
  21. 21.
    O’Brien S, Bernert RA, Logan JL, Lien YH (1997) Remission of posttransplant lymphoproliferative disorder after interferon alfa therapy. J Am Soc Nephrol 8(9):1483–1489PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Sung-Yong Kim
    • 1
  • Seok-Goo Cho
    • 2
    Email author
  • Sung-Won Kim
    • 3
  • Byung-Ok Choi
    • 4
  • Kyung-Sin Park
    • 5
  • Jihyang Lim
    • 6
  • Chang-Ki Min
    • 2
  • Yong-Goo Kim
    • 6
  • Jong-Wook Lee
    • 2
  • Woo-Sung Min
    • 2
  1. 1.Department of Hematology/Oncology, KonKuk University Medical CenterKonKuk UniversitySeoulSouth Korea
  2. 2.Catholic Blood and Marrow Transplantation Center, Seoul St. Mary’s HospitalThe Catholic University of KoreaSeoulSouth Korea
  3. 3.Department of Otolaryngology-Head and Neck SurgeryThe Catholic University of KoreaSeoulSouth Korea
  4. 4.Department of Radiation OncologyThe Catholic University of KoreaSeoulSouth Korea
  5. 5.Department of PathologyThe Catholic University of KoreaSeoulSouth Korea
  6. 6.Department of Laboratory Medicine, College of MedicineThe Catholic University of KoreaSeoulSouth Korea

Personalised recommendations